Do single-arm trials have a role in drug development plans incorporating randomised trials?

Pharmaceutical Statistics

Volumn 15, Issue 2, 2016, Pages 143-151

  Grayling, Michael J ^a   Mander, Adrian P ^a  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

optimal development plans; phase II clinical trial design; randomised two arm; single arm

Indexed keywords

ANTINEOPLASTIC AGENT; BAVITUXIMAB; CARBOPLATIN; PACLITAXEL;

ANALYTICAL ERROR; ANTINEOPLASTIC ACTIVITY; ARTICLE; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; INTERMETHOD COMPARISON; METHODOLOGY; NON SMALL CELL LUNG CANCER; NULL HYPOTHESIS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SYSTEMATIC ERROR; TREATMENT OUTCOME; TREATMENT PLANNING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PROTOCOL; DRUG DEVELOPMENT; HUMAN; LUNG NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962326240     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1726     Document Type: Article

References (36)

1. DiMasi JA, Grabowski HG,. Economics of new oncology drug development. Journal of Clinical Oncology 2007; 25: 209-16.
2. DiMasi JA, Hansen RW, Grabowski HG,. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003; 22: 151-185.
3. Stallard N, Whitehead J, Todd S, Whitehead A,. Stopping rules for phase II studies. British Journal of Clinical Pharmacology 2001; 51: 523-9.
4. Stone A, Wheeler C, Barge A,. Improving the design of phase II trials of cytostatic anticancer agents. Contemporary Clinical Trials 2007; 28: 138-45.
5. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC,. Recommended changes to oncology clinical trial design: revolution or evolution?. European Journal of Cancer 2008; 44: 8-11.
6. Ratain MJ, Sargent DJ,. Optimising the design of phase II oncology trials: the importance of randomisation. European Journal of Cancer 2009; 45: 275-280.
7. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D,. Randomized phase II designs. Clinical Cancer Research 2009; 15: 1883-90.
8. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D,. Randomized phase II trials: inevitable or inadvisable ? Journal of Clinical Oncology 2010; 28: 2641-7.
9. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D,. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research 2010; 16: 1764-69.
10. Stewart DJ,. Randomized phase II trials: misleading and unreliable. Journal of Clinical Oncology 2010; 28: e649-50.
11. Rubinstein L, LeBlanc M, Smith MA,. More randomization in phase II trials: necessary but not sufficient. Journal of the National Cancer Institute 2011; 103: 1075-77.
12. Sharma MR, Stadler WM, Ratain MJ,. Randomized phase II trials: a long-term investment with promising returns. Journal of the National Cancer Institute 2011; 103: 1093-100.
13. Jung SH,. Randomized phase II cancer clinical trials. Chapman & Hall: London, 2013.
14. Green SJ, Dahlberg S,. Planned versus attained design in phase II clinical trials. Statistics in Medicine 1992; 11: 853-62.
15. Simon R,. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10: 1-10.
16. Lee JJ, Feng L,. Randomised phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology 2005; 23: 4450-7.
17. Jennison C, Turnbull BW,. Group sequential methods with applications to clinical trials. Chapman & Hall: London, 1999.
18. Taylor JM, Braun TM, Li Z,. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Clinical Trials 2006; 3: 335-48.
19. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ,. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. Journal of Clinical Oncology 2010; 28: 1936-41.
20. Pond GR, Abassi S,. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Clinical Trials 2011; 8: 260-9.
21. Sambucini V,. Comparison of single-arm versus randomized phase II clinical trials: a Bayesian approach. Journal of Biopharmaceutical Statistics 2015; 25: 474-89.
22. De Ridder F,. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic & Clinical Pharmacology & Toxicology 2005; 96: 235-41.
23. Berry JD, Cudkowicz ME, Shefner JM,. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 2014; 15: 1-8.
24. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian approaches to clinical trials and health-care evaluation. Wiley-Blackwell: NJ, 2003; 158-61.
25. Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE,. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer 2014; 86: 231-6.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the united state, national cancer institute of canada. Journal of the National Cancer Institute 2000; 92: 205-16.
27. Mander AP, Thompson SG,. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemporary Clinical Trials 2010; 31: 572-8.
28. Lan KKG, DeMets DL,. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
29. Farrington CP, Manning G,. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Statistics in Medicine 1990; 9: 1447-54.
30. R Core Team. R: A language and environment for statistical computing, 2014. Available at: http://www.r-project. org/ (accessed 11.11.2015).
31. Bowden J, Mander A,. A review and re-interpretation of a group-sequential approach to sample size re-estimation in two stage trials. Pharmaceutical Statistics 2014; 13: 163-72.
32. O'Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, Oakley JE, Rakow T,. Uncertain judgements: eliciting experts' probabilities. John Wiley & Sons: London, 2006.
33. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH,. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006; 355: 2542-50.
34. Baghdadi R, Laffler MJ,. The next phase in oncology: FDA's Pazdur has new vision for drug development. The Pink Sheet 2013.
35. Englert S,. Flexible designs for single-arm phase II trials in oncology. Epubli: Berlin, 2014.
36. Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, Hobbs B, Ibrahim JG, Kinnersley N, Lindborg S, Micallef S, Roychoudhury S,. Thompson L (2014) Use of hisotircal control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics 2014; 13: 42-54.